Biogen (BIIB) competitors & alternatives
Health Care · NASDAQ
Biogen (BIIB)'s top competitors and alternatives — its most similar public companies — include AbbVie (ABBV), DENALI THERAPEUTICS INC (DNLI), VANDA PHARMACEUTICALS INC (VNDA), ROCKET PHARMACEUTICALS INC (RCKT), Ionis Pharmaceuticals (IONS), DESIGN THERAPEUTICS INC (DSGN), CAMP4 THERAPEUTICS CORP (CAMP), BridgeBio Pharma, Inc. (BBIO), Ultragenyx (RARE), Alnylam Pharmaceuticals (ALNY), CAPRICOR THERAPEUTICS INC (CAPR) and BioMarin Pharmaceutical (BMRN). These are Biogen's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top BIIB competitors & alternatives
-
AbbVieABBVHealth Care
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
$253.30 (as of 2026-07-22) · market cap $452.5B
-
DENALI THERAPEUTICS INCDNLIHealth Care
Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the…
$23.64 (as of 2026-07-22) · market cap $3.7B
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
CAMP4 THERAPEUTICS CORPCAMPHealth Care
CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy.
$3.11 (as of 2026-07-22) · market cap $166M
-
BridgeBio Pharma, Inc.BBIOHealth Care
BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in…
$82.66 (as of 2026-07-22) · market cap $16.2B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
CAPRICOR THERAPEUTICS INCCAPRHealth Care
Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for…
$18.91 (as of 2026-07-22) · market cap $1.1B
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
Not quite? Describe exactly what you want →
Peers are Biogen's closest public companies by shared sub-industry, sector and business themes. See the full profile: Biogen (BIIB).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.